236 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (1752)
- Addiction (19)
- Allergy, Asthma, & Immunology (13)
- All of Us Research Program - NIH (1)
- Autoimmune Disorders (29)
- Blood Disorders (33)
- Bone & Muscle (10)
- Cancer
(564)
- Bladder Cancer (13)
- Brain Cancer (12)
- Breast Cancer (60)
- Gastrointestinal (10)
- Gynecologic Cancer (30)
- Head and Neck Cancer (4)
- Kidney Cancer (7)
- Leukemia (64)
- (-) Liver Cancer (4)
- Lung Cancer (57)
- Lymphoma (24)
- Multiple Myeloma (24)
- Pancreatic Cancer (6)
- Prostate Cancer (25)
- Sarcoma (23)
- Skin Cancer (26)
- Solid Tumors (36)
- Thyroid Cancer (1)
- Uveal Melanoma (7)
- Child Development (4)
- COVID-19 (Coronavirus) (36)
- Critical Illness (1)
- Diabetes (21)
- Ear, Nose and Throat (12)
- Endocrine & Metabolic Disease (12)
- Eye (7)
- Gastrointestinal and Digestive Diseases (26)
- Hair and Skin Disorders (3)
- Headaches (5)
- Healthy Volunteers (187)
- Heart Disease (130)
- Infectious Disease (49)
- Insomnia (2)
- Kidney Disease (12)
- Liver Disease (53)
- Lung Disease (31)
- Meniere's Disease (1)
- Neurological Disorders (165)
- Nutrition (5)
- Obesity (10)
- Obstetrics & Gynecology (55)
- Pain Management (1)
- Pediatrics (103)
- Psychiatric Disorders (67)
- Rehabilitation (9)
- Stroke (7)
- Surgery (7)
- Transplant (48)
- Urology (4)
- Vascular Conditions (10)
Displaying 1 - 23 of 23
Condition: Cancer / Liver Cancer
Investigator: Elizabeth Verna, MD
Status: Currently Recruiting
This study aims to use new technology involving molecular and imaging tests to help detect liver cancer early in patients. Participants enrolled will participate in it for approximately 5 years. The purpose of this study is to determine if an experimental drug, INT-787, is safe and effective in patients who are hospitalized due to severe alcohol-associated…
Condition: Cancer / Liver Cancer
Investigator: Linda Wu, MD
Status: Closed
The purpose of this study is to compare the effects, good or bad, of tiragolumab plus atezolizumab plus bevacizumab versus placebo plus atezolizumab plus bevacizumab on patients with HCC. In this study, participants will be randomized you will get either tiragolumab plus atezolizumab plus bevacizumab or placebo plus atezolizumab plus bevacizumab. A placebo…
Condition: Blood Disorders / Amyloidosis
Investigator: Divaya Bhutani, MD
Status: Closed
The purpose of the study is to determine if the drug, CAEL-101 in combination with plasma cell treatment improves overall survival for patients who are diagnosed with stage 3b of AL amyloidosis. Patients who participate in this study will receive CAEL-101 as well as plasma cell treatment or Placebo as well as plasma cell treatment to compare the effects.
Condition: Blood Disorders / Amyloidosis
Investigator: Divaya Bhutani, MD
Status: Closed
The purpose of the study is to determine if the drug, CAEL-101 in combination with plasma cell treatment improves overall survival for patients who are diagnosed with stage 3a of amyloid light chain (AL) amyloidosis. Patients who participate in this study will receive CAEL-101 as well as plasma cell treatment or Placebo as well as plasma cell treatment to…
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to evaluate the safety and effectiveness of an antibody drug (STI-6129) in patients with AL amyloidosis that has returned or has not responded to treatment (relapsed/refractory). The study drug (STI-6129) will be given in 3 injections through a needle, into a vein as an intravenous (IV), with 21 days between each injection.
Condition: Lung Disease / Cystic Fibrosis
Investigator: Emily DiMango, MD
Status: Closed
This study is being done to learn more about the safety and effects of the combination of VX-661 and ivacaftor in subjects with Cystic Fibrosis (CF).
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
This is a research study for subjects that have been previously treated for systemic light chain (AL)amyloidosis (a disease in which abnormal protein deposits can damage organs and tissues in your body) and nowrequire further treatment. The main purpose of this study is to evaluate the safety and determine the maximum tolerated dose of aninvestigational new…
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to test for any good and bad effects of the study drug called isatuximab. Isatuximab may or may not improve your AL amyloidosis, but it could also cause side effects. Isatuximab is not approved by the Food and Drug Administration (FDA). Isatuximab has been shown to have good effects in some patients with recurring multiple…
Condition: Lung Disease / Cystic Fibrosis
Investigator: Emily DiMango, MD
Status: Closed
The main purpose of this study is to look at the effectiveness, safety, and tolerability of study drug CTX-4430 when compared to a placebo (sugar pill) taken once-daily for 48 Weeks in adult patients with CysticFibrosis (CF).
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The study is being done to see if the combination of bendamustine and dexamethasone will help people with amyloidosis that has returned after standard treatment. Bendamustine is currently approved by the Food and Drug Administration (FDA) for treatment of chronic lymphocytic leukemia (CLL) and is under clinical development in the United States for the…
Condition: Blood Disorders / Amyloidosis
Investigator: Divaya Bhutani, MD
Status: Closed
The purpose of this study is to see if daratumumab when given with three other drugs cyclophosphamide, bortezomib (VELCADE) and dexamethasone is useful for treating patients with Amyloid light chain Amyloidosis (also known as AL Amyloidosis). The study will look at what happens (both good and bad) when daratumumab is given with these three drugs compared to…
Condition: Lung Disease / Cystic Fibrosis
Investigator: Hossein Sadeghi, MD
Status: Closed
This study is for patients who have been prescribed tobramycin inhalation powder (TOBI Podhaler) or another inhaled medication used to treat cystic fibrosis patients whose lungs contain bacteria called Pseudomonas aeruginosa. The purpose of this research study is to assess how well TOBI Podhaler works on treating Pseudomonas aeruginosa in the lungs of…
Condition: Cancer / Liver Cancer
Investigator: Yvonne Saenger, MD
Status: Closed
The purpose of this study is to learn more about TPST-1120. The aims of the study are to find out if TPST-1120 can be given safely to people, to determine a safe dose of the study drug, if it is safe when given in combination with other anti-cancer drugs, what effects the drug may have, and to learn more about how the body processes the study drug. This is…
Condition: Lung Disease / Cystic Fibrosis
Investigator: Claire Keating, MD
Status: Closed
This study is being done to learn more about the safety and effectiveness of study drug VX-661 in combination with ivacaftor in patients aged 12 years and older with Cystic Fibrosis (CF). In this Study there are two treatment groups. If the patient meets all the rules for being in the Study, they willbe in one of the two treatment groups. The patient will…
Condition: Cancer / Liver Cancer
Investigator: Elizabeth Verna, MD
Status: Closed
Patients will be asked to participate in this research study because they have been diagnosed with hepatocellular carcinoma (HCC) which is a type of liver cancer. By doing this study, researchers hope to: Find out more about patients that have HCC including their age, race/ethnicity, and other medical conditions they may have; learn more about how…
Condition: Lung Disease / Cystic Fibrosis
Investigator: Emily DiMango, MD
Status: Closed
The purpose of this study is to assess how effective the study drug Pulmaquin is in the management of chronic lung infections with Pseudomonas aeruginosa in subjects with non cystic fibrosis (nonCF) bronchiectasis by evaluating the time to first pulmonary exacerbation. A pulmonary exacerbation is defined as the new appearance or worsening in 4 or more of…
Condition: Blood Disorders / Amyloidosis
Investigator: Thomas Brannagan, MD
Status: Closed
The purpose of this study is to evaluate the efficacy and safety of ION-682884 given for 24 months in patients with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN) also known as Familial Amyloid Polyneuropathy (FAP), and determine if it can help people with mild or moderate polyneuropathy. To be in this study you must have FAP and be…
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to evaluate whether study drug NEOD001 will improve survival in subjects with AL amyloidosis and/or increase the interval of time that they can go without requiring hospitalization for problems with their hearts. This study will also evaluate whether NEOD001 improves the function of subjects' organs that have been affected…
Condition: Lung Disease / Cystic Fibrosis
Investigator: Emily DiMango, MD
Status: Closed
The purpose of this study is to find out whether the study drug altaluren can help lung function and can reduce the symptoms associated with cystic fibrosis (CF), and decrease the number of hospitalizations and the use of antibiotics for CF-related lung infections. The study will also investigate whether the drug can help improve overall patient quality of…
Condition: Lung Disease / Cystic Fibrosis
Investigator: Claire Keating, MD
Status: Closed
This study is being done to learn more about the safety and effectiveness of VX-440 used in combination with tezacaftor and ivacaftor in patients with cystic fibrosis. VX-440 given in combination with tezacaftor and ivacaftor is an investigational drug; investigational means the drug is not approved by the Food and Drug Administration (FDA), and is still…
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to find out if MLN9708 plus dexamethasone improves against systemic light chain amyloidosis better than the physicians choice chemotherapy treatment. Physicians choice chemotherapy treatment is a treatment regimen that is commonly used to treat amyloidosis patients. The study will also determine if MLN9708 plus dexamethasone can…
Condition: Lung Disease / Cystic Fibrosis
Investigator: Claire Keating, MD
Status: Closed
The purpose of the ELEVATE CF study is to evaluate an oral investigational medication called VX-440 tosee if it is safe, effective, and well-tolerated when taken alone or with two other oral medications(VX-661 tezacaftor and ivacaftor) in people with cystic fibrosis (CF). This triple combination(TC) is being tested to see if it improves chloride transport (…
Condition: Blood Disorders / Amyloidosis
Investigator: Thomas Brannagan, MD
Status: Closed
HELIOS-A is a global Phase 3 randomized, open-label study designed to evaluate the safety and efficacy of ALN-TTRSC02 in adult patients with hATTR amyloidosis experiencing neurologic symptoms brought on by the disease. The study will also evaluate any changes in quality of life experienced by study participants. ALN-TTRSC02 utilizes the mechanism of RNA…